We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
AbbVie’s rheumatoid arthritis drug Humira (adalimumab) and six other drugs whose prices were raised in 2020 without supportive clinical data cost the U.S. health system $1.67 billion in annual drug spending, according to a new analysis released yesterday by the Institute for Clinical and Economic Review (ICER). Read More
The “new” J&J aims to strengthen its pharmaceuticals and medical devices portfolio, which is projected to rake in $77 billion in 2021 revenue. Read More
The Federal Trade Commission (FTC) has approved certain modifications to Bristol Meyers Squibb’s (BMS) divestiture agreements as part of the company’s 2019 acquisition of Celgene. Read More
Johnson & Johnson (J&J) plans to spin off its over-the-counter consumer products unit from its more lucrative prescription drugs and medical devices division, splitting itself into two publicly traded companies within the next 18 to 24 months. Read More
AstraZeneca is setting up a new business unit dedicated to overseeing its vaccines and antibody therapies as it looks to rebound from pandemic-era disappointments related to its COVID-19 jab co-developed with Oxford University. Read More
In a stunning decision, Oklahoma’s supreme court has reversed a $465 million verdict against Johnson & Johnson (J&J), regarding allegations the drugmaker contributed to the state’s public health crisis by misleadingly hawking prescription opioids. Read More
GRO Biosciences says the investment will support the company’s pipeline of protein therapeutics with properties “previously inaccessible to protein engineering.” Read More